Integration of cell biology, pharmacological modeling and statistical analysis. Part I: Cell biology and PK/PD in the Oncology paradigm

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 2, 2012, Pages 153-169

  Ananthakrishnan, Revathi ^a   Menon, Sandeep ^a  

^a NONE   (United States)

Author keywords

Biopolymer physics; Cell biology of cancer; Detection and treatment of cancer; Oncology clinical trials; PK PD modeling of Oncology data

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LETROZOLE; LEUPRORELIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TAMOXIFEN; TAXANE DERIVATIVE; TOSITUMOMAB; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESEARCH; CANCER STAGING; CARCINOGENESIS; CELL IMMORTALIZATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; COMPARTMENT MODEL; CYTOLOGY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; EARLY DIAGNOSIS; EARLY INTERVENTION; FOLLICULAR LYMPHOMA; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STATISTICAL ANALYSIS; STUDY DESIGN; TREATMENT RESPONSE;

EID: 84864041947     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.10.004     Document Type: Review

References (54)

1. Biesalski H.K., Bueno de Mesquita B., Chesson A., et al. European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. CA Cancer J Clin 1998, 48(3):167-176. discussion 164-6.
2. Roggli V.L., Sharma A., Butnor K.J., Sporn T., Vollmer R.T. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002, 26(2):55-65.
3. Alberti C. Cytoskeleton structure and dynamic behaviour: quick excursus from basic molecular mechanisms to some implications in cancer chemotherapy. Eur Rev Med Pharmacol Sci 2009, 13(1):13-21.
4. Smith D., Gentry B., Stuhrmann B., et al. The cytoskeleton: an active polymer scaffold. Biophys Rev Lett 2009, 4:179-188.
5. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Walter P. Molecular biology of the cell 2002, Garland Science. 4th ed.
6. Helfand B.T., Chang L., Goldman R.D. Intermediate filaments are dynamic and motile elements of cellular architecture. J Cell Sci 2004, 117(Pt 2):133-141.
7. Huber F., Käs J. Self-regulative organization of the cytoskeleton. Cytoskeleton 2011, 68(5):259-265.
8. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
9. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
10. Weinberg R.A. The biology of cancer 2007, Garland Science.
11. Lodish H.F., Berk A., Kaiser C.A., et al. Molecular cell biology 2000, W.H. Freeman. 4th ed.
12. Harley C.B. Telomerase is not an oncogene. Oncogene 2002, 21(4):494-502.
13. Aguda B.D. Kick-starting the cell cycle: from growth-factor stimulation to initiation of DNA replication. Chaos 2001, 11(1):269-276.
14. Kimball Biology Pages. Available from http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/O/Oncogenes.html.
15. Carroll P.E., Okuda M., Horn H.F., et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999, 18(11):1935-1944.
16. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21(3):485-495.
17. Haupt S., Berger M., Goldberg Z., Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003, 116(Pt 20):4077-4085.
18. Guck J., Schinkinger S., Lincoln B., et al. Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence. Biophys J 2005, 88(5):3689-3698.
19. Moustakas A., Stournaras C. Regulation of actin organisation by TGF-beta in H-ras-transformed fibroblasts. J Cell Sci 1999, 112(Pt 8):1169-1179.
20. Rao J.Y., Hurst R.E., Bales W.D., et al. Cellular F-actin levels as a marker for cellular transformation: relationship to cell division and differentiation. 3rd Cancer Res 1990, 50(8):2215-2220.
21. Olson M.F., Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 2009, 26(4):273-287.
22. Hernandez P., Tirnauer J.S. Tumor suppressor interactions with microtubules: keeping cell polarity and cell division on track. Dis Model Mech 2010, 3(5-6):304-315.
23. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011, 30(2):127-138.
24. Willis N.D., Wilson R.G., Hutchison C.J. Lamin A: a putative colonic epithelial stem cell biomarker which identifies colorectal tumours with a more aggressive phenotype. Biochem Soc Trans 2008, 36(Pt 6):1350-1353.
25. Park S., Koch D., Cardenas R., Käs J., Shih C.K. Cell motility and local viscoelasticity of fibroblasts. Biophys J 2005, 89(6):4330-4342.
26. Chu E., DeVita V.T. Physicians' cancer chemotherapy drug manual 2010, Jones and Bartlett Publishers, LLC.
27. Cavalli F., Kaye S.B., Hansen H.H., Armitage J.O., Piccart-Gebhart M.J. Textbook of medical Oncology 2009, Informa UK Ltd. 4th ed.
28. Perry M.C. The chemotherapy source book 2008, Lippincott Williams & Wilkins. 4th ed.
29. Takimoto C.H., Calvo E. Principles of oncologic pharmacotherapy in cancer management: a multidisciplinary approach 2008, Cmp United Business Media. 11th ed.
30. Jordan M.A., Thrower D., Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. IMPLICATIONS for the role of microtubule dynamics in mitosis. J Cell Sci 1992, 102(Pt 3):401-416.
31. Jordan M.A., Thrower D., Wilson L. Mechanism of inhibition of cell proliferation by Vinca Alkaloids. Cancer Res 1991, 51(8):2212-2222.
32. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002, 2(1):1-17.
33. Bhat K.M., Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007, 13(10):2849-2854.
34. Sarli V., Giannis A. Kinesin motor inhibitors as effective anticancer drugs, checkpoint responses in cancer therapy 2008, Humana Press, p. 207-26.
35. Rao J.Y., Li N. Microfilament actin remodeling as a potential target for cancer drug development. Current Cancer Drug Targets 2004, 4(4):345-354.
36. Allingham J.S., Zampella A., D'Auria M.V., Rayment I. Structures of microfilament destabilizing toxins bound to actin provide insight into toxin design and activity. Proc Natl Acad Sci USA 2005, 102(41):14527-14532.
37. Braet F., Soon L., Vekemans K., Thordarson P., Spector I. Actin-binding drugs: an elegant tool to dissect subcellular processes in endothelial and cancer cells. Protein Rev 2008, 8:37-49.
38. Spector I., Braet F., Shochet N.R., Bubb M.R. New anti-actin drugs in the study of the organization and function of the actin cytoskeleton. Microsc Res Tech 1999, 47(1):18-37.
39. Lahat G., Zhu Q.S., Huang K.L., et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010, 16(5):e10105. 4.
40. Jordan V.C., Furr B.J.A. Hormone therapy in breast and prostate cancer 2009, Humana Press.
41. Kurzrock R., Markman M. Targeted cancer therapy 2008, Humana Press.
42. Dietel M. Targeted therapies in cancer 2007, Springer-Verlag.
43. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007, 357(1):39-51.
44. Paul B., Trovato J.A., Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008, 65(18):1703-1710.
45. Gabrielsson J.L. Utilization of physiologically based models in extrapolating pharmacokinetic data among species. Fundam Appl Toxicol 1991, 16(2):230-232.
46. Dixit R., Boelsterli U.A. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 2007, 12(7-8):336-342.
47. Miller K., Louie A., Baltch A.L., Smith R.P., Davis P.J., Gordon M.A. Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans. Antimicrob Agents Chemother 1998, 42(9):2405-2409.
48. Gabrielsson J., Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications 2007, Swedish Pharmaceutical Press. 4th ed.
49. Ananthakrishnan R., Gona P. Pharmacological modeling and biostatistical analysis of a new drug. Open Access J Clin Trials 2010, 2:59-82.
50. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991, 32:669-670.
51. Marchbanks K., Dudley M.N., Posner M.R., Darnowski J. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Pharmacotherapy 1995, 15(4):451-457.
52. Chow S., Liu J. Design and analysis of bioavailability and bioequivalence studies 2009, Chapman & Hall/CRC.
53. Normolle D., Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol 2006, 24(27):4426-4433.
54. LoRusso P.M., Jones S.F., Koch K.M., et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008, 26(18):3051-3056.